Clinical manifestations of familial medullary thyroid carcinoma

Biomed Pharmacother. 2004 Jul-Aug;58(6-7):348-50. doi: 10.1016/j.biopha.2004.05.002.

Abstract

We conducted a large-scale nation-wide questionnaire survey to ascertain the status of familial medullary thyroid carcinoma (MTC) in Japan in 2002. Out of a total of 271 MTC cases (male to female ratio 1:1.4), multiple endocrine neoplasia (MEN) 2A accounted for 83 cases (30.6%), familial MTC (FMTC) for 14 cases (5.1%), MEN for 11 cases (4.1%), and sporadic MTC for 163 cases (60.1%). Mean age at the time of diagnosis was 35.6 in MEN2A, 34.6 in FMTC, 30.5 in MEN2B, and 47.6 in sporadic MTC. Forty-five percent of MEN2A patients had pheochromocytoma and 11% of MEN2A patients had parathyroid disorders when MTC was diagnosed. Finally, the RET oncogene test yielded the largest number of initial findings that led to diagnosis of familial MTC.

MeSH terms

  • Adrenal Gland Neoplasms / epidemiology
  • Adrenal Gland Neoplasms / genetics
  • Adult
  • Carcinoma, Medullary / epidemiology*
  • Carcinoma, Medullary / genetics*
  • Female
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Multiple Endocrine Neoplasia Type 2a / epidemiology
  • Multiple Endocrine Neoplasia Type 2a / genetics
  • Multiple Endocrine Neoplasia Type 2b / epidemiology
  • Multiple Endocrine Neoplasia Type 2b / genetics
  • Oncogene Proteins / genetics
  • Parathyroid Diseases / epidemiology
  • Parathyroid Diseases / genetics
  • Pheochromocytoma / epidemiology
  • Pheochromocytoma / genetics
  • Proto-Oncogene Proteins c-ret
  • Proto-Oncogenes
  • Receptor Protein-Tyrosine Kinases / genetics
  • Thyroid Neoplasms / epidemiology*
  • Thyroid Neoplasms / genetics*

Substances

  • Oncogene Proteins
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • Receptor Protein-Tyrosine Kinases